HIV Specific Binding Molecules

A nucleic acid molecule encoding a TCR alpha chain and/or a TCR beta chain,

• wherein the TCR alpha chain comprises a variable domain amino acid sequence selected from:
• a)
• (SEQ ID NO:
• 2)
• AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS
• GKSPELIMKL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ
• PSDSATYLCA VRTNSGYALN FGKGTSLLVT P;
• b)
• (SEQ ID NO:
• 3)
• AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS
• GKSPELIMFL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ
• PSDSATYLCA VRTNAGYALN FGKGTSLLVT P;
• or
• c)
• (SEQ ID NO:
• 4)
• AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS
• GKSPELIMKL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ
• PSDSATYLCA VRTNAGYALN FGKGTSLLVT P;
• optionally with an N-terminal methionine (SEQ ID NOs:
• 41-43), and/or
• the TCR beta chain comprises the variable domain amino acid sequence:
• (SEQ ID NO:
• 5)
• DAGVTQSPTH LIKTRGQQVT LRCSPKSGHD TVSWYQQALG
• QGPQFIFQAV RGVERQRGNF PDRFSGHQFP NYSSELNVNA
• LLLGDSALYL CASSDTVSYE QYFGPGTRLT VT_,
• optionally with an N-terminal methionine (SEQ ID NO:
• 44).

A pharmaceutical composition comprising a specific binding molecule having the property of binding to SLYNTVATL (SEQ ID NO:

• 1) in complex with HLA-A*02 and comprising a TCR alpha chain variable domain and a TCR beta chain variable domain,
• wherein the alpha chain variable domain amino acid sequence comprises an amino acid sequence selected from:
• a)
• (SEQ ID NO:
• 2)
• AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS
• GKSPELIMKL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ
• PSDSATYLCA VRTNSGYALN FGKGTSLLVT P;
• b)
• (SEQ ID NO:
• 3)
• AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS
• GKSPELIMFL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ
• PSDSATYLCA VRTNAGYALN FGKGTSLLVT P;
• or
• c)
• (SEQ ID NO:
• 4)
• AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS
• GKSPELIMKL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ
• PSDSATYLCA VRTNAGYALN FGKGTSLLVT P;
• optionally with an N-terminal methionine (SEQ ID NOs:
• 41-43), and
• the beta chain variable domain comprises the amino acid sequence:
• (SEQ ID NO:
• 5)
• DAGVTQSPTH LIKTRGQQVT LRCSPKSGHD TVSWYQQALG
• QGPQFIFQAV RGVERQRGNF PDRFSGHQFP NYSSELNVNA
• LLLGDSALYL CASSDTVSYE QYFGPGTRLT VT_,
• optionally with an N-terminal methionine (SEQ ID NO:
• 44), together with one or more pharmaceutically acceptable carriers or excipients.

A method of treating HIV infection or AIDS in a human subject, comprising administering a therapeutically effective amount of a specific binding molecule having the property of binding to SLYNTVATL (SEQ ID NO:

• 1) in complex with HLA-A*02 and comprising a TCR alpha chain variable domain and a TCR beta chain variable domain,
• wherein the alpha chain variable domain comprises an amino acid sequence selected from:
• a)
• (SEQ ID NO:
• 2)
• AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS
• GKSPELIMKL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ
• PSDSATYLCA VRTNSGYALN FGKGTSLLVT P;
• b)
• (SEQ ID NO:
• 3)
• AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS
• GKSPELIMFL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ
• PSDSATYLCA VRTNAGYALN FGKGTSLLVT P;
• or
• c)
• (SEQ ID NO:
• 4)
• AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS
• GKSPELIMKL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ
• PSDSATYLCA VRTNAGYALN FGKGTSLLVT P;
• optionally with an N-terminal methionine (SEQ ID NOs:
• 41-43), and
• the beta chain variable domain comprises the amino acid sequence:
• (SEQ ID NO:
• 5)
• DAGVTQSPTH LIKTRGQQVT LRCSPKSGHD TVSWYQQALG
• QGPQFIFQAV RGVERQRGNF PDRFSGHQFP NYSSELNVNA
• LLLGDSALYL CASSDTVSYE QYFGPGTRLT VT_,
• optionally with an N-terminal methionine (SEQ ID NO:44).